In a press release to the community today, Skyhawk Therapeutics announced topline results from their Phase 1 trial:
Skyhawk Therapeutics Announces Positive Topline Results from Parts A and B of its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease, Reaching 72% Huntingtin mRNA Reduction
- Skyhawk's SKY-0515 demonstrated dose-dependent huntingtin (HTT) mRNA reduction in healthy volunteers, with 72% reduction at the highest dose tested in the multiple ascending dose study
- SKY-0515 was generally well tolerated at all doses tested
- Given these positive topline results, we anticipate dosing in the patient arm of the study in Q3 2024 and initiation of a Phase 2 study early next year